<DOC>
	<DOCNO>NCT02733341</DOCNO>
	<brief_summary>Major heart attack cause number factor , two major furring coronary artery atheroma sudden clot formation area lead blockage interruption blood flow . The clots lead heart attack largely make clot blood cell ( platelet ) health repair blood vessel inhibit spontaneous bleeding . One main treatment strategy heart attack make cell less `` sticky '' . Aspirin main stay anti-platelet treatment United Kingdom ( UK ) addition one three oral antiplatelet agent act platelet activation pathway ( P2Y12 receptor ) license use . When patient admit major heart attack , treat emergency primary percutaneous coronary intervention ( PPCI ) technique wire balloon use reopen coronary artery usually stent ( slotted metal tube ) place keep artery open . Aspirin one P2Y12 inhibitor agent give prevent clot show reduce negative event follow heart attack angioplasty stent insertion . There increase data , include institution , show set heart attack , oral P2Y12 inhibitor poorly absorb little effect time need , i.e . soon dose primary PCI perform . All three current P2Y12 inhibitor agent take tablet form immediately emergency PPCI procedure . It appear healthy stable patient agent take least 30 min 2 hour adequate effect . In heart attack patient angioplasty procedure usually perform well within timescale . Furthermore , patient heart attack normal drug absorption blood divert away stomach gut activity suppress drug morphine . In current study , patient major heart attack give standard oral agent , Ticagrelor , newer intravenous agent Cangrelor prior PPCI .</brief_summary>
	<brief_title>The Effect IV Cangrelor Oral Ticagrelor Study</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Angina , Unstable</mesh_term>
	<mesh_term>Cangrelor</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Patients present STEMI eligible PPCI Able give verbal assent pre procedure write consent follow procedure . Age ≥18 year No contraindication Cangrelor Ticagrelor Thienopyridine naïve If patient give verbal assent unable provide write consent later stage due incapacitation , presumed consent continue . The reason patient becomes incapacitated becomes unable provide write consent record data collection . Be unable provide verbal assent write consent Allergic Aspirin P2Y12 antagonists trial Have preexisting cardiogenic shock Previous myocardial infarction Have concurrent septic inflammatory disease e.g . rheumatoid arthritis , lupus , pneumonia . Already take P2Y12 inhibitor Known bleeding diathesis Significant active bleed History intracranial hemorrhage Patients treat formal anticoagulation ( Vitamin K antagonist , Factor II Xa inhibitor ) indication anticoagulation first four hour study period . Example patient know atrial fibrillation , pulmonary embolism deep vein thrombosis . Known severe renal dysfunction require renal replacement therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Adenosine Diphosphate</keyword>
	<keyword>Cardiovascular Magnetic Resonance ( CMR )</keyword>
	<keyword>Index microvascular resistance ( IMR )</keyword>
	<keyword>Vasodilator stimulate phosphoprotein phosphorylation ( VASP )</keyword>
	<keyword>Pharmacodynamic</keyword>
	<keyword>Antiplatelet</keyword>
	<keyword>Myocardial Infarction ( MI )</keyword>
	<keyword>Cangrelor</keyword>
	<keyword>Ticagrelor</keyword>
	<keyword>Coronary artery bypass graft ( CABG )</keyword>
	<keyword>Primary percutaneous coronary intervention ( PPCI )</keyword>
</DOC>